Physician profile
Laura E Davis
NPI 1154571446
$8,106.30
in general payments reported to CMS, 2019-2025
35 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $1,543 · 2023: $1,757 · 2024: $1,288 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,156.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,624.94 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Accurian |
| Abbvie INC. | $1,050.83 | 2021-2025 | |
| Boston Scientific Corporation | $759.28 | 2024-2025 | Intracept, General - Pain Management |
| Collegium Pharmaceutical, INC. | $732.61 | 2021-2025 | Belbuca, Xtampza |
| Pfizer INC. | $179.65 | 2023-2025 | |
| Depuy Synthes Sales INC. | $177.58 | 2021-2025 | Monovisc, Orthovisc |
| Merz Pharmaceuticals, LLC | $169.99 | 2021-2024 | Xeomin |
| Si-Bone, INC. | $148.17 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $102.71 | 2023-2024 | Belsomra, Gardasil, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $100.34 | 2021-2022 | |
| Amgen INC. | $99.27 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $97.07 | 2024-2025 | |
| Vertos Medical, INC. | $95.37 | 2024 | Mild Device Kit |
| Allergan, INC. | $86.06 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $84.06 | 2023 | Iovera, Exparel, Zilretta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $62.93 | 2022-2023 | Vyepti |
| Curonix LLC | $51.51 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $48.75 | 2023-2025 | Sprint Pns System |
| Pacira Therapeutics, INC. | $44.89 | 2021 | |
| Nevro Corp. | $41.69 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $36.79 | 2022 | |
| Avanos Medical | $34.12 | 2022-2023 | Standard Rf Disposables |
| Acacia Pharma INC | $33.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $31.29 | 2021 | |
| Hikma Pharmaceuticals USA | $27.49 | 2022 | |
| Averitas Pharma INC. | $26.37 | 2023 | Qutenza |
| Tersera Therapeutics LLC | $23.43 | 2022 | |
| Bioventus LLC | $22.72 | 2022 | |
| Scilex Pharmaceuticals INC. | $21.65 | 2021 | |
| Redhill Biopharma INC. | $19.44 | 2022 | |
| Currax Pharmaceuticals LLC | $15.13 | 2021 | |
| Impel Pharmaceuticals INC. | $15.02 | 2023 | Trudhesa |
| Abbott Laboratories | $14.80 | 2025 | Eterna |
| Lilly USA, LLC | $13.76 | 2021 | |
| Biogen, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.